In an era where global health consciousness has reached an all-time high, the focus of the supplement industry is shifting from reactive treatments to proactive, cellular-level fortification. At the center of this paradigm shift is a breakthrough in "postbiotic" technology—a category of health-promoting compounds that are challenging the long-standing dominance of probiotics. Leading this charge is IMMUSE™, a science-backed ingredient developed by Kyowa Hakko, which promises to activate the body’s natural defenses by targeting the "commanders" of the immune system.
As consumers increasingly seek out evidence-based wellness solutions to support active lifestyles, the introduction of IMMUSE™ represents a significant milestone in nutritional science. By focusing on the plasmacytoid dendritic cell (pDC), this novel postbiotic offers a more comprehensive approach to immune health than traditional supplements, which often only target a single facet of the body’s complex defense network.
Main Facts: A Breakthrough in Immune Orchestration
The fundamental challenge of maintaining a healthy immune system lies in its complexity. The human immune system is a vast network of cells, tissues, and organs that must work in perfect harmony to defend against pathogens while maintaining internal balance. Most traditional immune supplements, such as Vitamin C, Zinc, or basic probiotics, focus on supporting specific white blood cells, such as Natural Killer (NK) cells. While beneficial, this approach is often piecemeal.
IMMUSE™ (technically known as Lactococcus lactis strain Plasma, or LC-Plasma) functions differently. It is a heat-killed (postbiotic) lactic acid bacteria that specifically activates the plasmacytoid dendritic cell (pDC). In biological terms, pDCs are often described as the "commanders-in-chief" of the immune system. When a pDC is activated, it sends a signal to a wide array of other immune cells, including NK cells, Killer T-cells, Helper T-cells, and B-cells. This creates a coordinated, system-wide response rather than a localized or limited activation.
According to Karen Todd, a registered dietitian and Vice President of Global Brand Marketing at Kyowa Hakko USA, the unique nature of this ingredient allows it to be integrated into a variety of delivery formats, from traditional capsules and tablets to modern gummies, powders, and functional beverages. Its status as a non-GMO, allergen-free, and vegetarian-friendly ingredient further aligns it with the "clean label" demands of contemporary consumers.
Chronology: From Discovery to Global Application
The journey of IMMUSE™ from a laboratory observation to an award-winning health ingredient spans over three decades of intensive scientific inquiry.
The 1990s: The Discovery of the Commander Cell
The scientific foundation for IMMUSE™ was laid in the late 1990s when researchers first identified the plasmacytoid dendritic cell (pDC). Before this discovery, the scientific community understood that various immune cells worked to protect the body, but the mechanism that coordinated these diverse cells remained somewhat elusive. The identification of pDCs as the central regulators of both innate and adaptive immune responses opened a new door for preventative medicine.
The Research Phase: Testing the Strains
Following the discovery of pDCs, the research team at Kirin Holdings (the parent company of Kyowa Hakko) began a massive screening process. Their goal was to find a specific strain of lactic acid bacteria that could directly stimulate these "commander" cells. Most lactic acid bacteria are digested or pass through the system without interacting with pDCs. After testing more than 100 different strains, the team identified Lactococcus lactis strain Plasma (LC-Plasma) as the only strain capable of this specific activation.

Innovation in Stability: The Transition to Postbiotic
While many immune-supporting bacteria are sold as "live" probiotics, Kyowa Hakko utilized a proprietary heat-treatment process to transform LC-Plasma into a postbiotic. This was a strategic technological move. By using heat-killed cells, the researchers ensured that the ingredient remained stable at room temperature and could survive the harsh environment of the digestive tract to reach the necessary immune receptors. This stability also made it possible to incorporate the ingredient into a wider range of food and beverage products without the refrigeration requirements associated with live cultures.
2023 and Beyond: Market Integration
By October 2023, IMMUSE™ had established itself as a premier ingredient in the global supplement market. Backed by 30 published studies and 15 human clinical trials, the product moved from niche scientific circles into mainstream wellness, targeting athletes, working professionals, and families looking for year-round respiratory and systemic support.
Supporting Data: The Science of Cellular Defense
The efficacy of IMMUSE™ is not merely anecdotal; it is rooted in a robust body of clinical evidence that distinguishes it from many other "immune-boosting" products on the market.
Clinical Trial Results
Of the 30 published studies on LC-Plasma, 15 are human clinical trials. These include 13 efficacy studies and two safety studies. The data consistently demonstrates that daily intake of IMMUSE™ supports respiratory health and reduces the incidence of fatigue-related immune dips.
One significant area of study has been its impact on high-intensity athletes. It is a well-known phenomenon in sports medicine that extreme physical exertion can lead to a temporary "immune window" of vulnerability. Clinical trials have shown that athletes taking IMMUSE™ reported fewer days of feeling "under the weather" and maintained better overall physical condition during training cycles compared to placebo groups.
Mechanism of Action
The data reveals a "cascade effect" triggered by the ingredient:
- Direct Activation: LC-Plasma reaches the small intestine and interacts with pDCs located in the Peyer’s patches (lymphoid tissue).
- Interferon Alpha Production: Once activated, pDCs produce Interferon-alpha (IFN-α), a signaling protein.
- System-Wide Mobilization: The IFN-α signals NK cells, T-cells, and B-cells to move into a state of readiness.
- Comprehensive Defense: This multi-pronged mobilization provides a more robust defense against environmental stressors and seasonal challenges than products that only stimulate a single cell type.
Official Responses: Insights from Kyowa Hakko
Karen Todd, RD, has been a vocal advocate for the role of postbiotics in modern nutrition. In her discussions regarding the product’s impact, she emphasizes the intersection of lifestyle and biology.
"Life is measured in moments—both big and small," Todd explains. "Whether you’re hiking with friends, working toward a promotion, or spending quality time with your kids, you want to feel your best. But if your natural defenses are weakened, it’s hard to keep up."

Todd points out that the modern environment is inherently taxing on the immune system. Factors such as chronic stress, lack of sleep, and nutritional gaps create a constant challenge for the body. "Maintaining a healthy immune system with daily support is crucial, and IMMUSE™ is the postbiotic for the job," she notes.
Regarding the specific benefits for active individuals, Todd highlights that the fatigue associated with high-intensity workouts is often the first sign of a struggling immune system. "IMMUSE™ can help support you through exercise and a busy day. It helps you stay healthy to enjoy all the scenic miles and summit views," she says, referring to the brand’s focus on supporting "life’s adventures."
Implications: The Future of the Postbiotic Market
The rise of IMMUSE™ carries significant implications for the future of the health and wellness industry. It signals a move away from the "probiotic-only" mindset that has dominated the gut-health conversation for the last two decades.
The Postbiotic Advantage
As a postbiotic, IMMUSE™ offers several advantages for manufacturers and consumers alike. Its heat-stability means it has a longer shelf life and does not require the expensive cold-chain logistics that often plague the probiotic industry. This makes immune support more accessible and convenient for the average consumer, who can now find these benefits in shelf-stable snacks, drinks, and daily supplements.
Shifting Consumer Expectations
Consumers are becoming more sophisticated. They are no longer satisfied with vague claims of "wellness"; they are looking for specific biological mechanisms and clinical proof. The success of IMMUSE™ suggests that transparency and rigorous scientific backing are becoming the new baseline for success in the dietary supplement space.
Proactive vs. Reactive Health
Finally, the introduction of "daily" immune support ingredients like IMMUSE™ reflects a broader societal shift toward proactive health management. Rather than waiting for the onset of seasonal illness to take high doses of vitamins, consumers are adopting a "fortification" mindset—strengthening their cellular defenses year-round to ensure they can "show up" for their professional and personal lives.
In conclusion, IMMUSE™ represents a sophisticated bridge between traditional fermentation wisdom and cutting-edge immunology. By targeting the pDC "commander" cells, it provides a comprehensive, science-backed solution for an era where health is seen not just as the absence of illness, but as the foundation for an active, adventurous life. As more research emerges, the role of postbiotics in maintaining the delicate balance of the human immune system is likely to become a cornerstone of daily nutrition.
